This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Victor Grifols Selected As "Business Leader Of The Year 2011" By The Spain - U.S. Chamber Of Commerce


BARCELONA, Spain, Dec. 6, 2011 /PRNewswire/ -- Victor Grifols Roura, president and managing director of Grifols, has been selected as the "Business Leader of the Year 2011" by the Spain – U.S. Chamber of Commerce, the premier forum fostering commercial, economic and industrial relations between Spain and the United States. This award, given annually, recognizes the professional career of business leaders who stand out in their industries, as well as their contribution to the globalization of the economy. In the case of Victor Grifols, his leadership as sales manager of Grifols since 1979, and as president and managing director since 1987 has driven the transition of Grifols and allowed it to grow from a family company to the third largest producer of plasma protein therapies worldwide.

(Logo: )

The award will be presented by Angeles Gonzalez Sinde, Minister of Cultural Affairs of the Government of Spain during the gala dinner that will take place on December 6th, 2011 at the Hotel Pierre in New York, and attendees will include notable political and business figures from both Spain and the United States.

Victor Grifols Roura studied Business Science at the University of Barcelona and joined Grifols in 1973. A man of great strategic and commercial vision, as the Commercial Director he was the architect of the restoration of Grifols' sales network in Spain. Additionally, as managing director, he was responsible for the in-depth reorganization of the company that allowed it to establish the basis for the multinational group that Grifols is today.

For Victor Grifols, international expansion has always been and continues to be essential to ensure the growth of his organization. In 1988 he opened the company's first international subsidiary in Portugal, inaugurating the process of progressive expansion of Grifols in other markets, whose first objective was Latin America, though entrance into the United States market was always the long-term goal.

During the 1990's the international expansion of the group took off, and one of the decisive factors of this was the acquiring of two Food & Drug Administration licenses in 1995: the Establishment License for the production plant in Parets del Valles ( Barcelona, Spain), and the Product License for its product, Albumin.

In 1998, Miami was designated as the site for the first American subsidiary of Grifols, with Central America and the Caribbean as its principal areas of influence, followed by Argentina and Chile in 1991. The disappearance of the Soviet Bloc in 1992 created the opportunity for a new subsidiary in the Czech Republic, and the following year, Mexico was chosen as the next country for expansion.

In 1997, European expansion began through acquisitions. The purchase of subsidiaries of Alpha Therapeutic Corporation in the United Kingdom, Germany and Italy permitted a rapid penetration into those markets and generated enough confidence for the company to leap to the United States, a world leader in the blood derivatives sector. In the years 2002 and 2003, two acquisitions planted the roots of Grifols in the US: the purchase of SeraCare, that ensured the supply of raw materials through the expansion of its plasma acquisition centers, and a large part of the assets of Alpha Therapeutic Corporation, including its plasma division and protein purification plants for the in Los Angeles.

Presently, Grifols maintains a strong presence on the North American market and the internationalization of the group has translated into a global commercial presence including more than 90 countries with direct subsidiaries in 24.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $93.24 -0.41%
FB $117.81 -0.21%
GOOG $701.43 0.82%
TSLA $211.53 -4.96%
YHOO $36.94 2.61%


Chart of I:DJI
DOW 17,660.71 +9.45 0.05%
S&P 500 2,050.63 -0.49 -0.02%
NASDAQ 4,717.0940 -8.5450 -0.18%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs